Schering-Plough to pay $435 million in marketing, pricing case

Share this article:
Schering-Plough and its Schering Sales Corp. division were sentenced to pay $435 million Wednesday as part of a settlement with the Justice Department over accusations the companies engaged in off-label marketing and lied about drug prices, the Associated Press reported. Under the settlement first announced in August, Schering Sales Corp. pleaded guilty to conspiracy and agreed to pay a criminal fine of $180 million. Parent company, Schering-Plough agreed to pay another $255 million to resolve civil aspects of the case. The sentencing ends an investigation by the Justice Department and the US Attorney’s office in Boston that began in 2001. Federal investigators said Schering-Plough marketed drugs for uses that had not been approved by the FDA. An example was Temodar, a drug the FDA approved to treat a type of brain tumor called anaplastic astrocytoma. Prosecutors said Schering-Plough promoted Temodar to treat several other types of brain cancer, indications which the FDA had not approved. The company also promoted the unapproved use of Intron A for the treatment of cancer on the surface of the bladder, prosecutors said. Although doctors are allowed to prescribe drugs for unapproved uses, drug companies are prohibited from marketing drugs for off-label uses. US District Judge Patti Saris scolded Schering and the entire pharma industry for promoting non-FDA approved uses for drugs. She noted that several other major drug companies have also been fined for illegal marketing including Pfizer, which in 2004 agreed to pay $430 million on allegation that Warner-Lambert, which Pfizer acquired in 2000, promoted non-approved uses of the anti seizure drug Neurontin. “You cannot thumb your nose at the FDA,” Saris said in the AP report. “At the end of the day, you can’t market off-label. … It’s wrong.” Brien O’Connor, an attorney for Schering-Plough, said in the AP report that the company never lied to doctors about the uses the drugs had been approved for, but simply spoke to doctors and gave them peer-reviewer articles about other uses for the drugs. “We told the truth about Temodar and Intron and we didn’t mislead the doctors,” O’Connor said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...